Grant

A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy

Sponsored by Longboard Pharmaceuticals, Inc.

Active

$543.6K Funding

2 People

External

Related Topics

clinical trials, pharmacology, safety, efficacy, dose escalation

People

Kirsten Anderson
(CD)
Senior VP Health Sciences﹒Research Compliance Administrator IV
David Labiner
Principal Investigator (PI)
Neurology﹒Department Head